RHA® Redensity Eye Versus No-treatment for the Infra-Orbital Hollows
A Randomized, Blinded Evaluator, No-treatment Control, Multicenter, Prospective Clinical Study of RHA® Redensity Eye for the Treatment of Moderate to Severe Tissue Volume Deficiencies in the Infraorbital Regions
Sponsor: Teoxane SA
This NA trial investigates Infra-orbital Hollows and Tear-trough Deformity and is currently completed. Teoxane SA leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Completed NA
Status: Withheld → Completed · Phase: None → NA
-
Feb 2025 — Feb 2026 [monthly]
Withheld
-
Sep 2024 — Feb 2025 [monthly]
Withheld
-
Aug 2023 — Sep 2024 [monthly]
Withheld
-
Sep 2022 — Aug 2023 [monthly]
Withheld
▶ Show 5 earlier versions
-
Jul 2022 — Sep 2022 [monthly]
Withheld
-
Dec 2021 — Jul 2022 [monthly]
Withheld
-
Feb 2021 — Dec 2021 [monthly]
Withheld
-
Jan 2021 — Feb 2021 [monthly]
Withheld
-
Nov 2020 — Jan 2021 [monthly]
Withheld
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Teoxane SA
For direct contact, visit the study record on ClinicalTrials.gov .